Open 7 days a week Mon–Fri: 8:00 AM – 8:00 PM Sat–Sun: 8:00 AM – 4:00 PM

Book an Appointment

Hepatitis B & C Treatment Springfield Lakes – Expert Viral Hepatitis Management

Hepatitis B and C are serious viral infections that affect the liver and can lead to chronic disease, cirrhosis, and liver cancer if left untreated. At Health Hub Springfield Lakes, our experienced medical team provides comprehensive viral hepatitis diagnosis, treatment, and monitoring in Springfield Lakes, utilizing the latest antiviral therapies and evidence-based management strategies to achieve optimal patient outcomes.

Understanding Viral Hepatitis

Hepatitis B and C are blood-borne viruses that cause inflammation of the liver, leading to acute illness and potentially chronic infection with serious long-term complications.

Hepatitis B Virus (HBV)

  • DNA virus: Hepadnavirus family
  • Chronic infection: 5-10% of adults, 90% of infants
  • Global burden: 296 million people chronically infected
  • Transmission: Blood, sexual contact, mother-to-child
  • Vaccine preventable: Effective vaccination available

Hepatitis C Virus (HCV)

  • RNA virus: Flavivirus family
  • Chronic infection: 75-85% of infected individuals
  • Global burden: 58 million people chronically infected
  • Transmission: Primarily blood-borne
  • Curable: Direct-acting antivirals achieve 95%+ cure rates

Disease Progression

  • Acute hepatitis: Initial infection phase
  • Chronic hepatitis: Persistent infection >6 months
  • Liver fibrosis: Progressive scarring
  • Cirrhosis: Advanced liver disease
  • Hepatocellular carcinoma: Liver cancer risk

Hepatitis B: Transmission and Risk Factors

Transmission Routes

  • Blood exposure: Needle sharing, transfusions, medical procedures
  • Sexual transmission: Unprotected sex with infected partner
  • Perinatal transmission: Mother to child during birth
  • Household contact: Sharing personal items (razors, toothbrushes)
  • Occupational exposure: Healthcare workers, laboratory staff

High-Risk Groups

  • People who inject drugs: Shared needles and equipment
  • Men who have sex with men: Higher transmission rates
  • Multiple sexual partners: Increased exposure risk
  • Healthcare workers: Occupational exposure
  • Household contacts: Close contact with infected individuals
  • Immigrants from endemic areas: Asia, Africa, Pacific Islands

Prevention Strategies

  • Hepatitis B vaccination: Most effective prevention
  • Safe sex practices: Condom use, partner testing
  • Avoid needle sharing: Drug use harm reduction
  • Universal precautions: Healthcare settings
  • Screening blood products: Transfusion safety

Hepatitis C: Transmission and Risk Factors

Primary Transmission

  • Injection drug use: Current or past needle sharing (60% of cases)
  • Blood transfusions: Before 1992 screening (20% of cases)
  • Healthcare exposure: Needle sticks, contaminated equipment
  • Hemodialysis: Dialysis-associated transmission
  • Tattoos/piercings: Non-sterile equipment use

Less Common Transmission

  • Sexual transmission: Low risk but possible
  • Perinatal transmission: 5% mother-to-child transmission
  • Household transmission: Sharing personal items rarely
  • Unknown source: 10-15% of cases
  • Organ transplantation: Pre-screening era

At-Risk Populations

  • Current injection drug users: Highest risk group
  • Former injection drug users: Historical exposure
  • Blood transfusion recipients: Before 1992
  • Healthcare workers: Occupational exposure
  • HIV-positive individuals: Co-infection common
  • Prisoners: Higher prevalence rates

Symptoms and Clinical Presentation

Acute Hepatitis Symptoms

  • Fatigue: Severe tiredness and weakness
  • Nausea and vomiting: Gastrointestinal upset
  • Abdominal pain: Right upper quadrant discomfort
  • Loss of appetite: Reduced food intake
  • Low-grade fever: Mild temperature elevation
  • Joint pain: Arthralgia and muscle aches

Chronic Hepatitis Symptoms

  • Often asymptomatic: No obvious symptoms for years
  • Fatigue: Persistent tiredness
  • Abdominal discomfort: Mild right upper quadrant pain
  • Cognitive difficulties: Brain fog, concentration problems
  • Depression: Mood changes and mental health impact
  • Extrahepatic manifestations: Joint pain, skin conditions

Advanced Disease Signs

  • Jaundice: Yellowing of skin and eyes
  • Ascites: Abdominal fluid accumulation
  • Edema: Leg and ankle swelling
  • Spider angiomata: Vascular skin lesions
  • Palmar erythema: Red palms
  • Hepatic encephalopathy: Confusion, altered mental state

Comprehensive Diagnostic Testing

Initial Screening Tests

Hepatitis B Testing

  • HBsAg: Hepatitis B surface antigen (current infection)
  • Anti-HBc: Core antibody (past or current infection)
  • Anti-HBs: Surface antibody (immunity/vaccination)
  • HBeAg: e-antigen (high infectivity)
  • Anti-HBe: e-antibody (lower infectivity)

Hepatitis C Testing

  • Anti-HCV: Hepatitis C antibody (exposure history)
  • HCV RNA: Viral load (active infection)
  • HCV genotype: Strain identification for treatment
  • Core antigen: Alternative to RNA testing
  • Reflex testing: Automatic RNA testing if antibody positive

Monitoring and Assessment Tests

  • Liver function tests: ALT, AST, bilirubin, albumin
  • Complete blood count: Platelets, hemoglobin
  • Coagulation studies: INR, PT/PTT
  • Alpha-fetoprotein: Liver cancer screening
  • Quantitative HBV DNA: Viral load monitoring
  • Fibroscan: Non-invasive fibrosis assessment

Additional Testing

  • HIV testing: Co-infection screening
  • Hepatitis A immunity: Vaccination needs
  • Hepatitis D: Co-infection in HBV patients
  • Autoimmune markers: Rule out other liver diseases
  • Iron studies: Hemochromatosis screening

Hepatitis B Treatment

Treatment Indications

  • High viral load: HBV DNA >20,000 IU/ml (HBeAg+) or >2,000 IU/ml (HBeAg-)
  • Elevated ALT: >2x upper limit of normal
  • Significant fibrosis: Fibroscan >8 kPa or biopsy F2+
  • Family history: Liver cancer or cirrhosis
  • Age considerations: >40 years with detectable HBV DNA

First-Line Antiviral Agents

  • Tenofovir DF: 245mg daily, high barrier to resistance
  • Tenofovir AF: 25mg daily, improved renal/bone safety
  • Entecavir: 0.5mg daily, high efficacy, good safety profile
  • Duration: Long-term or indefinite treatment
  • Monitoring: 3-6 monthly viral load and safety labs

Treatment Goals

  • Viral suppression: Undetectable HBV DNA
  • ALT normalization: Liver enzyme improvement
  • HBeAg seroconversion: Immune control marker
  • Prevent progression: Avoid cirrhosis and liver cancer
  • Quality of life: Symptom improvement

Special Populations

  • Pregnancy: Safe antiviral options available
  • Co-infection: HIV, HCV, HDV management
  • Immunosuppressed: Prophylaxis and monitoring
  • Transplant recipients: Prevent reactivation
  • Healthcare workers: Occupational considerations

Hepatitis C Treatment

Direct-Acting Antivirals (DAAs)

  • Sofosbuvir/Velpatasvir: Pan-genotypic regimen
  • Glecaprevir/Pibrentasvir: 8-12 weeks treatment
  • Sofosbuvir/Ledipasvir: Genotype 1 and 4
  • Elbasvir/Grazoprevir: Genotype 1 and 4
  • Cure rates: >95% sustained virologic response

Treatment Duration

  • Treatment-naive: 8-12 weeks typically
  • Treatment-experienced: 12-24 weeks
  • Cirrhosis: May require longer duration
  • Genotype considerations: Some regimens genotype-specific
  • Ribavirin addition: Selected cases only

Monitoring During Treatment

  • Week 4: Early virologic response
  • End of treatment: Treatment completion response
  • SVR12: Sustained response 12 weeks post-treatment
  • Safety monitoring: Drug interactions, side effects
  • Liver function: Improvement assessment

Treatment Challenges

  • Drug interactions: Extensive interaction profile
  • Adherence: Importance of completing course
  • Reinfection risk: Ongoing risk behaviors
  • Access issues: Cost and availability
  • Special populations: Pregnancy, kidney disease

Post-Treatment Monitoring

Hepatitis B Follow-up

  • Lifelong monitoring: Even with treatment
  • Viral load: Every 6 months on treatment
  • Liver cancer screening: 6-monthly ultrasound and AFP
  • Treatment response: HBeAg seroconversion monitoring
  • Drug resistance: If virologic breakthrough

Hepatitis C Post-SVR Care

  • SVR confirmation: HCV RNA at 12 and 24 weeks
  • Liver function: Improvement over time
  • Fibrosis regression: May occur post-cure
  • Cancer screening: Continue if cirrhosis present
  • Reinfection monitoring: High-risk individuals

Long-term Complications

  • Cirrhosis management: Ongoing care needed
  • Liver cancer surveillance: Regular screening
  • Cardiovascular health: Reduced risk post-treatment
  • Kidney function: Monitor if comorbidities
  • Mental health: Depression and fatigue improvement

Prevention and Public Health

Hepatitis B Prevention

  • Universal vaccination: Childhood immunization program
  • High-risk group vaccination: Targeted programs
  • Post-exposure prophylaxis: HBIG and vaccination
  • Safe practices: Healthcare and community settings
  • Partner notification: Contact tracing and testing

Hepatitis C Prevention

  • Harm reduction: Needle exchange programs
  • Safe injection practices: Education and resources
  • Healthcare infection control: Standard precautions
  • Screening programs: High-risk population testing
  • Treatment as prevention: Reducing transmission

Contact Tracing

  • Partner notification: Sexual and household contacts
  • Healthcare worker exposure: Occupational health protocols
  • Outbreak investigation: Source identification
  • Testing recommendations: Risk-based screening
  • Follow-up care: Ensure appropriate treatment

Living with Viral Hepatitis

Lifestyle Modifications

  • Alcohol cessation: Complete abstinence recommended
  • Healthy diet: Support liver function
  • Regular exercise: Improve overall health
  • Weight management: Reduce fatty liver
  • Medication review: Avoid hepatotoxic drugs

Psychosocial Support

  • Counseling services: Coping with chronic illness
  • Support groups: Peer connections
  • Mental health care: Depression and anxiety treatment
  • Substance abuse treatment: Addiction services
  • Social services: Financial and practical support

Preventing Transmission

  • Safe sex practices: Condom use for HBV
  • Don’t share personal items: Razors, toothbrushes
  • Disclose status: Inform healthcare providers
  • Blood donation: Avoid donating blood
  • Family planning: Pregnancy counseling

Why Choose Health Hub Springfield Lakes for Viral Hepatitis Care?

Specialized Hepatitis Expertise

  • Experienced in viral hepatitis management
  • Latest antiviral therapy protocols
  • Comprehensive monitoring programs
  • Multidisciplinary care approach

Advanced Diagnostic Services

  • Complete hepatitis screening panels
  • Viral load and genotype testing
  • Non-invasive fibrosis assessment
  • Liver cancer surveillance programs

Integrated Care Programs

  • Addiction medicine services
  • Mental health support
  • Immunization programs
  • Contact tracing and partner notification

Convenient Springfield Lakes Location

  • Accessible location with parking
  • Flexible appointment scheduling
  • Bulk billing options available
  • Confidential consultation services

Schedule Your Hepatitis Consultation

Early diagnosis and treatment of viral hepatitis can prevent serious complications. Our expert medical team at Health Hub Springfield Lakes is ready to provide comprehensive evaluation and cutting-edge treatment.

Contact Health Hub Springfield Lakes:

  • 📞 Phone: +61 7 3778 4888
  • đŸ„ Address: 18 Springfield Lakes Boulevard, Springfield Lakes QLD 4300
  • 🌐 Website: healthhubspringfieldlakes.com.au/
  • 📧 Email: info@healthhubspringfield.com.au

Take control of your liver health – book your viral hepatitis consultation with Health Hub Springfield Lakes today.